Dr Galsky on the FDA Approval of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

Related Keywords

Matthew Galsky ,Tisch Cancer Institute Of Mount Sinai ,Translational Research ,Medical Oncology ,Genitourinary Medical Oncology ,Bladder Cancer ,Tisch Cancer Institute ,Mount Sinai ,